Psilera, Inc., a biotech company that focuses on creating new treatments for challenging neurological conditions, has named Scott W. Rairigh as its Executive Vice President of Corporate Development. In this new position, Rairigh will be in charge of business development, handle investor relations, and help plan how the company’s potential drugs will be brought to market as Psilera moves its drug candidates through clinical trials.
Health Technology Insights: Santhera Partners with Ikris Pharma to Distribute AGAMREE India
Dr. Chris Witowski, the CEO of Psilera, is happy about Rairigh joining the leadership team. He says Scott is a dynamic and thoughtful leader whose skills will be important in speeding up the development of Psilera’s neuroplastogen pipeline. Dr. Witowski believes Rairigh’s experience will help the company fulfill its goal of making treatments that change how neurological care is provided.
Before working at Psilera, Rairigh held high-level positions at Celgene and Bristol Myers Squibb, most recently leading global commercial strategy for Precision Medicine in areas like oncology, hematology, and neuroscience. He also worked for 17 years at Johnson & Johnson in various leadership roles within pharmaceutical and diagnostic departments, where he concentrated on personalized medicine for conditions such as Alzheimer’s disease and depression. Rairigh has a Bachelor of Science degree from Towson University, a Master of Science from Johns Hopkins University, and a leadership certificate from Harvard Business School.
Health Technology Insights: Dimora PHMB Cleanser Brings Clinical-Grade Wound Care Into Everyday Homes
Scott Rairigh is excited about taking on a bigger role at Psilera, highlighting the chance to make a real difference for patients and their families. Having been on Psilera’s board since 2019, he praises the company’s leadership, including Dr. von Salm and Dr. Witowski, for their commitment to creating groundbreaking medicines that address neurological disorders like dementia and addiction by altering and activating brain pathways.
This appointment is a strategic step for Psilera to add a seasoned executive with both commercial experience and a strong grasp of neuroscience and personalized medicine, putting the company in a better position for ongoing growth and success in developing new treatments.
Health Technology Insights: Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
